Evaluation of response on tumor targeted therapy        XU Jian-ming. Affiliated Hospital, Academy of Military Medical Sciences (the 307 Hospital of PLA), Beijing 100071, China
Abstract    The development of targeted therapies is a major breakthough in the treatment of cancer. In contrast to traditionally cytotoxic agents, targeted therapies are designed to interfere with specific aberrant transduction pathway involved in tumorigenesis,  slow the growth of tumors, limit the development of metastases, or evoke necrosis and cavitation. Therefore, the effect evaluation of the new targeted agents is more complex. The RECIST criteria by using tumor size are not sufficient for the evaluation of objective response, and are no longer suitable for setting of study endpoints. Molecular and functional imaging will provide realistic evaluation for targeted agents treatment response by incorporating biological information into RECIST criteria.